Search results

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical tria

We are a community of passionate project and engineering makers. We founded Peleven to make the investment and project life as easy and successful as possible for our customers from the pharmaceutical, biotechnological as well as chemical research and their industry.

As an independent pharma consulting company, we have supported pharma and biotech companies since 2007. With a team of more than 25 consultants, Qualified Persons and support staff, three offices and hundreds of pharma partners in over 30 countries worldwide, we are ready to solve your challenges.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Provectis Healthcare AG is a global healthcare company based in Basel and the commercial partner of choice to the innovative biopharma. We advance the innovation through launch, commercialization and brand building in Europe, Middle East and Asia.

Quant Biomarkers develops next-gen urinary biomarkers for cardio-kidney-metabolic diseases. Its RenoRisk™ test detects kidney injury 3–6 years earlier than standard markers, supported by AI software for improved risk stratification, monitoring, and management.

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

MEDICE has always developed and produced medicinal products almost exclusively at the Iserlohn site and concentrates in the prescription area on CNS, renal medicine and dialysis medicine. Salmon Pharma is the Swiss subsidiary of MEDICE.

SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

Skyvor Medical is a Basel-based digital health company, founded by seasoned professionals with 35 years of drug development experience in global pharma. Skyvor Medical develops AI-powered digital platforms to accelerate the protocol design, feasibility and data management in clinical trials.

Clinical development strategy and execution, without noise.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.

steerBIO GmbH is a boutique management consultancy for the VC, biotech and pharmaceutical industry. We support your complex R&D challenges associated with modern drug development and medical launch by integrating deep knowledge, honest analysis and strategic thinking in a co-creative approach.

Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.

Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders through the modulation of a new drug target in the endocannabinoid system enabling restoration of the natural functioning of the brain.

We are a leading international company offering end-to-end solutions ranging from the automation, process engineering and validation of biotech and pharmaceutical plants. With more than two decades of experience in GMP environments, we have in-depth knowledge of the applicable regulations.  

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies.

ten23 health, headquartered in Basel, Switzerland, was founded in 2021. We are the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test tomorrow’s medicines.

The Bloc Switzerland is a creative, full-service agency with 30 years of experience in impactful health communication. Our medical and creative teams craft corporate identities, websites, social media campaigns, brand brochures, and mode of action and corporate videos.

TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

Vaderis Therapeutics AG is a clinical stage biotech focusing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020, and a Series B investment of USD 152 million in August 2026.

Strategic, operational, business and finance advice to companies in the Life Sciences with focus on business planning and implementation (including strategies to secure financing, M&A and financial planning), clinical development/medical affairs and technical development/operations (CMC).

VISCHER’s life sciences practice group is advising over 60 private and public companies under Swiss law in: transactions & financing, partnering & licensing, know-how & innovation management; and regulatory, administrative procedures & compliance.

We offer state‑of‑the‑art, ready‑to‑use laboratories dedicated to research and scientific projects. Located close to office spaces, our ecosystem sits in the heart of Basel, one of Europe’s most dynamic scientific hubs.

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. The company targets validated biology in respiratory and dermatology.

Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.